HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Sept. 19, 2024 /PRNewswire/ — Sirnaomics Ltd. (the "Company", Stock Code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, today announced that the company in collaboration with Dr. Mark Nestor’s team from the Center for Clinical and Cosmetic Research in Miami Florida has jointly published a major breakthrough for its novel siRNA therapeutics revealing a novel mechanism of action of a significant reduction of adipose tissue in preclinical animal models. This groundbreaking work entitled "Novel injectable polypeptide nanoparticle encapsulated siRNA targeting TGF-β1 and COX-2 for localized fat reduction I: Preclinical in vitro and animal models", published at Journal of Cosmetic Dermatology, 2024; 00:1-11, creates a solid foundation for the Company’s RNAi-based therapeutic program for focal fat reduction treatment.

The study evaluates the efficacy of STP705, an injectable containing siRNA encapsulated within histidine-lysine polypeptide (HKP) nanoparticles targeting transforming growth factor β1 (TGF- β1) and cyclooxygenase-2 (COX-2), crucial mediators in adipocyte differentiation and fat retention, using in vitro experiments on mouse preadipocytes and in vivo trials using Diet Induced Obese (DIO) mice and Yucatan minipigs. The study results indicated that STP705 effectively reduced the expression of TGF-β1 and COX-2, with a notable decrease in adipocyte volume and lipid content without apparent adverse systemic effects. In DIO mice, the HKP- siRNA complex demonstrated precise localization to injected adipose tissue, maintaining significant gene silencing, and detectable levels of siRNA for up to 14 days post-administration. The data in minipigs showed a significant reduction in subcutaneous adipose tissue thickness up to 56 days post-administration. In conclusion: These studies support the use of targeted-siRNA therapy specifically targeting TGF-β1 and COX-2, for localized fat reduction, offering a potential minimally invasive alternative to current fat reduction methods.

Mark S. Nestor, M.D., Ph.D., a recognized world expert in clinical research in clinical Dermatology and aesthetics, who is a Voluntary Professor at the Department of Dermatology and Cutaneous Surgery and the Department of Surgery, Division of Plastic Surgery at the University of Miami, Miller School of Medicine and serves as Director of the Center for Clinical and Cosmetic Research™ and the Center for Cosmetic Enhancement®, Aventura, Florida, is the senior author of this publication; he comments: "The results of all of the pre-clinical studies clearly indicate the significant potential of STP705 to use as a safe and effective method of reducing localized fat accumulation and sets the stage for the clinical pathway for this indication."

Dr. Patrick Lu, the founder, Chairman and CEO of Sirnaomics, comments, "The latest publication indicated that Sirnaomics’ leading drug candidate, STP705, has exhibited a novel mechanism of action, by specifically silencing TGF-β1 and COX-2 in the subdermal adipose tissue, resulted in localized fat reduction.  The preclinical studies not only showed that It is safe and very well-tolerated, but also achieved preliminary efficacy in inducing adipocyte apoptosis and tissue remodeling, suggesting a safer alternative or adjunct to existing fat reduction therapies."

About Sirnaomics

Sirnaomics is an RNA therapeutics biopharmaceutical company that focuses on the discovery and development of Sirnaomics is an RNA therapeutics biopharmaceutical company with product candidates in preclinical and clinical stages that focuses on the discovery and development of innovative drugs for indications with medical needs and large market opportunities. Sirnaomics is the first clinical-stage RNA therapeutics company to have a strong presence in both Asia and the United States. Based on its proprietary delivery technologies: Polypeptide Nanoparticle Formulation and the 2nd generation of GalNAc conjugation, the Group has established an enriched drug candidate pipeline. Sirnaomics is currently holding a leadership position on advancing RNAi therapeutics for oncology application with multiple successes of its clinical programs for STP705 (Phase IIa, IIb) and STP707 (Phase I). The ongoing Phase I study of STP122G represents the first drug candidate of GalAhead™ technology entering clinical development with an encouraging therapeutic efficacy and safety readouts. Learn more at: www.sirnaomics.com.

Source : Sirnaomics Announces Demonstration of a Novel Mechanism of Action of Its siRNA Therapeutics for Focal Fat Reduction in Journal of Cosmetic Dermatology

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SHANGHAI, Sept. 19, 2024 /PRNewswire/ — KONE Corporation, a global leader in the elevator and escalator industry, announces its new strategy called "Rise" for 2025–2030. With this new strategy, KONE aims to lead in employee and customer experience, sustainability and innovations, as well as growth and profitability.

To reach this ambition, KONE has defined four strategic shifts: 1) Accelerate digital to fundamentally transform how KONE does service; 2) Drive modernization to unleash growth opportunities; 3) Win residential to lead in the industry’s largest segment; and 4) Cut carbon to drive customer value and differentiation. At the core of KONE’s strategy are people, and KONE wants to be the easiest company to work for and to work with.  

"We are setting the bar high with our new strategy, not only for us and our stakeholders, but for the whole industry. The nature of megatrends impacting us – urbanization, technological development, and sustainability – is changing and creating exciting new opportunities for us, especially in service and modernization. As our environment is changing, it highlights the importance of our resilient business model. We need bold actions and new perspectives. With more speed, courage, and simplicity, we will change the status quo, and we will do it by leveraging our capabilities in digitalization, by leading the way in sustainability and innovation, and in the end, by offering the best value and experiences to our customers," says Philippe Delorme, President and CEO, KONE Corporation.

"I am confident that with our dedicated employees, we will reach our ambitious targets for the good of our customers, employees, and the planet. This is our opportunity to fulfill KONE’s purpose to shape the future of cities," he continues.  

KONE’s ambition and financial targets

KONE’s ambition is to lead in three dimensions in line with the new strategy:

#1 choice for employees and customers Innovation and sustainability Growth and profitability

 The company’s long-term financial targets remain unchanged:

Growth: Faster than the market Profitability: To reach an EBIT margin of 16% Cash flow: Improved working capital rotation

KONE is setting the following mid-term financial targets to be achieved by the end of 2027:

Growth: Mid-single-digit sales growth Profitability: Adjusted EBIT margin of 13–14%

The new strategy and targets will come into effect from January 1, 2025, onwards.

Read more
More detailed description of the megatrends, ambition level, four shifts, and core is available at https://www.kone.com/en/company/strategy/.

Previous press releases are available at https://www.kone.com/en/news-and-insights/releases/.     

About KONE
At KONE, our purpose is to shape the future of cities. As a global leader in the elevator and escalator industry, we move two billion people every day, making their journeys safe, convenient, and reliable with smart and sustainable People Flow®. In 2023, KONE had annual sales of EUR 11.0 billion, and at the end of the year over 60,000 employees in more than 60 countries. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland.

www.kone.com

Source : KONE announces its new ambitious strategy for 2025-2030

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

BENGALURU, India, Sept. 19, 2024 /PRNewswire/ — Sheaffer has launched its new collection, called the Sheaffer Coffee Edition, its latest in highlighting the intrinsic bond that exists between two time-honoured passions. Founded in 1913 by Walter A. Sheaffer, the brand has been synonymous for innovation and quality craftsmanship in writing instruments. The addition of this latest collection is an attempt at toasting the eternal relationship between writing and coffee, a pairing long known to have inspired creativity for generations.

Sheaffer Coffee Edition Range

The Sheaffer Coffee Edition consists of two distinct sets of pens, each designed to embody the spirit of coffee culture. The first, the Sheaffer 100 Coffee Edition, features a robust color palette for those who prefer a strong cup of coffee. The second, the Sheaffer VFM Coffee Edition, offers a more subdued design for enthusiasts of lighter brews.

Every detail of the Coffee Edition pens has been meticulously crafted to reflect the essence of coffee. The high-quality brown nibs and the ombre body design are inspired by the swirling patterns found in a cup of coffee. Additionally, each pen prominently displays a signature motif, allowing for personal expression.

Accompanying the launch is a creative reimagining of the product packaging, which features the thematic message #TheWriteKindOfCoffee. This new design enhances the unboxing experience, reinforcing the connection between writing and coffee for consumers.

"For years now, coffee has been inspiring people to write, and this in turn inspired us to come up with a Sheaffer Coffee Edition pen, to celebrate this immortal bond. Meticulously crafted, this collection honours the enduring appeal of analog while embracing innovation. The two variants, inspired by different coffee roasts, reflect our commitment to personal preferences. As we continue to push boundaries, Sheaffer’s legacy of excellence remains our guiding principle." — Nikhil Ranjan, Managing Director, Sheaffer.

The Sheaffer Coffee Edition aims to appeal not only to pen enthusiasts but also to coffee lovers, offering a unique opportunity to merge these two passions. As writers seek inspiration in their daily rituals, the Coffee Edition promises to provide a perfect blend of functionality and style.

For more details, please visit:
Website | Instagram

For further information, contact:
Mr. Tim Williams
[email protected]

Source : Sheaffer Coffee Edition Launched, Unveiling the Connection Between Writing and Coffee

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

SINGAPORE, Sept. 19, 2024 /PRNewswire/ — Fullerton Health is proud to announce the launch of its 2023 Sustainability Report. Understanding the urgency of the climate agenda, FHG, in the second year of Sustainability reporting, has incorporated a carbon plan. In addition to highlighting the company’s ongoing efforts to enhance sustainability across its operations in Singapore, the Philippines and beyond, FHG has also put in place policies and metrics to govern and measure our contributions toward a greener world. As a leading healthcare provider in Asia, Fullerton Health remains committed to reducing its environmental footprint while continuing to provide top notch medical services.

2023 Fullerton Health Sustainability Report

The report outlines key achievements in energy efficiency, emissions reductions, and sustainable business practices in FY2023. It also reflects Fullerton Health’s broader vision of integrating sustainability into healthcare delivery for the benefit of future generations.

Remarked Ms Margareta Laminto, Chief Sustainability Officer, "Our 2023 sustainability report reflects our current commitments and future ambitions to employ healthcare services and technology to benefit our communities and the environment. Through significant dedication of our people, we have made steady improvements, and I look forward to helping lead even greater gains across the healthcare industry and ecosystem. We will continue to invest in initiatives that sustain our long-term vision to provide affordable and accessible care for all."

Key Highlights of the 2023 Sustainability Report:

Energy Management and Emissions Reduction: In 2023, Fullerton Health’s operations in Singapore achieved a significant reduction in Scope 2 emissions, recording 1,897 tCO₂e from purchased electricity usage, with an energy consumption of 4,550.82 MWh. In the Philippines, total energy consumption was 4,367.05 MWh, with Scope 2 emissions totaling 3,091.27 tCO₂e. Scope 1 and Scope 2 Emissions Monitoring: The report includes comprehensive data on emissions from direct operations (Scope 1) and electricity usage (Scope 2). In the Philippines, Scope 1 emissions, primarily from fuel consumption, were recorded at 208.02 tCO₂e, showcasing the company’s focus on tracking and reducing direct emissions. Caring for People and Communities: Fullerton Health reinforced its commitment to building healthier communities through various outreach programs and partnerships. Initiatives like health screenings, community wellness drives, and educational workshops have positively impacted vulnerable populations, ensuring that care extends beyond clinics and into the heart of communities. Upholding Good Business Conduct: Fullerton Health remains committed to the highest standards of ethics and integrity. The report highlights the company’s efforts in upholding transparent and responsible business practices, ensuring compliance with regulations, and fostering a culture of accountability across all operations. Sustainability Governance: Fullerton Health has established dedicated sustainability committees and energy management teams to ensure ongoing monitoring and improvement of sustainability efforts across all markets.

These highlights demonstrate Fullerton Health’s holistic approach to sustainability, prioritising environmental stewardship, community care, and good business conduct for long-term growth.

"We are proud to share our progress in making Fullerton Health a more sustainable and environmentally responsible organisation," said Mr Ho Kuen Loon, Group CEO. "Our 2023 Sustainability Report reflects our strong commitment to sustainability and our role in contributing to a healthier planet. We recognise that sustainability is a continuous journey, and we are dedicated to making meaningful progress each year."

Fullerton Health will continue to integrate sustainability into its operations, partnering with stakeholders, clients, and communities to achieve shared environmental goals. The company remains committed to transparent reporting and accountability as it works toward a greener and healthier future.

Click to read the full Sustainability Report.

–  End –

About Fullerton Health

Fullerton Health is a leading integrated health system in Asia. Founded in Singapore in 2010, today the Company serves clients through over 550 owned healthcare facilities and a large global network of healthcare providers across nine markets in Asia Pacific. Fullerton Health’s value proposition is the integration of healthcare service offerings with customised management and advisory capabilities, in line with its purpose to deliver affordable and accessible care for all in Asia.

For more information on Fullerton Health, please visit http://www.fullertonhealth.com/ 

Source : Fullerton Health Unveils 2023 Sustainability Report, Strengthening Commitment to a Greener Future

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Bata Celebrates 130 Years with a new Brand Campaign: "Make Your Way" 

LAUSANNE, Switzerland, Sept. 19, 2024 /PRNewswire/ — Bata, one of the world’s leading footwear companies, proudly celebrates its 130th anniversary with a new brand campaign named: "Make Your Way." This milestone marks a celebration of Bata’s rich heritage, and an exciting evolution aimed at positioning the brand as one of the top choices worldwide. 

Make your Way – Key Visual

A New Era for Bata

The "Make Your Way" campaign reflects Bata’s renewed focus on style, comfort, and affordability, aiming to attract a younger, trend-conscious audience while honouring its strong heritage. 

"This campaign is about inspiring self-expression and confidence. At Bata, we make shoes to accompany consumers as they create their own path in life and build their road to the future," says Sandeep Kataria, Global CEO of Bata. 

Strategic Vision

The new positioning, "Stylish, comfort-enhanced, affordable shoes for every side of you to make your way" aims to connect with today’s fashion-conscious consumers, to expand Bata customers base and drive further growth. It will be communicated through Bata’s key labels: "Bata", "Bata Comfit," and "Bata Red Label." This strategy positions Bata as the only major high-street footwear Retailer genuinely targeting ‘Every Side of You’ through authentic and heritage-rich in-house brands, covering every aspect of consumer life: dress, leisure and sport. 

Global Campaign Rollout

Developed with the agency &Rosàs, the global campaign includes media investments, in-store storytelling, and a redesign of Bata’s e-commerce and social media approach.

Special Initiatives

It will also feature do-good marketing efforts to inspire and support women across various disciplines. Starting in September in Europe, Bata will introduce a special 130th-anniversary edition of women’s ballerinas, supporting women in ballet and dance, fostering participation from diverse backgrounds, and aiding women facing economic challenges. The Ballerinas are a fashionable reinterpretation of the original Batovka, an innovative shoe launched in 1897 by Bata, which embodied the company’s vision about quality & affordability. 

About Bata Group

Bata is one of the world’s leading shoemakers, selling more than 150 million pairs of shoes annually. With comfortable fit, stylish designs, affordable prices, and responsible manufacturing, Bata customers can feel good in their shoes – from their head to their toes. Founded in 1894, the family-owned business operates in over 56 countries across five continents. Bata designs, manufactures, and retails its own footwear, constantly innovating to find the perfect fit. 

About &Rosàs

Founded in 2003, &Rosàs is a leading advertising and communications agency based in Barcelona, known for its consistency, market awareness, and loyalty. 

Press Contact 

Sarah Stocchetti
Global Corporate Communications at Bata Group 
E-Mail: [email protected] 
Mobile: +41 79 724 60 68 

Source : "Make Your Way" Bata unveils brand evolution

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network